Providers Clinical Support System Medication Assisted Treatment Grant

The Provider’s Clinical Support System – Medication Assisted Treatment Grant, issued by the Substance Abuse and Mental Health Services Administration (SAMHSA) under the U.S. Department of Health and Human Services, is a forecasted federal funding opportunity intended to address the escalating opioid crisis in the United States. As part of its broader public health mission, SAMHSA seeks to expand access to evidence-based care for opioid use disorders (OUD), with a specific focus on improving access to medication-assisted treatment (MAT) through increased provider training and awareness. This grant initiative is aligned with the national goal of reducing opioid overdose deaths and promoting the use of FDA-approved medications as part of a comprehensive approach to addiction treatment. The primary objective of this funding opportunity is to provide resources to national medical organizations that are already authorized under the Drug Addiction Treatment Act of 2000 (DATA) to conduct provider training. These organizations include the American Society of Addiction Medicine (ASAM), American Academy of Addiction Psychiatry (AAAP), American Medical Association (AMA), American Osteopathic Academy of Addiction Medicine (AOAAM), and the American Psychiatric Association (APA). The selected grantee will be responsible for expanding and enhancing training for primary care providers, focusing on the evidence-based treatment of OUD, the safe and effective treatment of chronic pain, and the appropriate use of MAT. Spending under this grant will likely cover the design, delivery, and evaluation of training programs; development of educational materials; engagement with stakeholders; and dissemination of best practices in MAT. While cost sharing is not required, the awarded entity is expected to have the organizational infrastructure and professional reach to deliver training at a national level. The expected funding amount is $2,000,000, though the ceiling and floor amounts for individual awards have not been specified. Only one award is anticipated under this opportunity, making it highly competitive and targeted. The eligibility for this grant is exclusive to the five national medical organizations authorized under the DATA 2000 act. These organizations have demonstrated experience and the legal authority to train providers who seek to prescribe Schedule III medications approved by the FDA for treating addictive disorders. This exclusive eligibility ensures that the training is delivered by credible and experienced national entities with significant influence across the healthcare system. The opportunity’s narrow eligibility scope reflects its strategic intent to ensure widespread and uniform implementation of MAT training. As a forecasted opportunity, specific application deadlines, start dates, and award dates are not yet confirmed. However, the estimated post date for the full funding opportunity announcement is February 15, 2022, and the forecast remains active as of December 11, 2025. Once published, applicants will likely need to submit through Grants.gov, following the federal grant application standards which may include a project narrative, budget justification, and institutional qualifications. Humberto Carvalho is listed as the point of contact for further inquiries, and can be reached via email at Humberto.Carvalho@samhsa.hhs.gov or by phone at (240) 276-2974. In terms of project timeline, once awarded, the grantee would likely be expected to commence work promptly, in line with SAMHSA’s broader funding cycle for fiscal year 2022. Although this is a forecasted opportunity, it is worth noting that such funding initiatives tend to recur annually or biannually, reflecting the persistent national priority to combat opioid misuse. Thus, organizations that do not receive funding this cycle may have future opportunities for engagement, and all potential applicants should monitor SAMHSA’s grants portal closely for updated details and deadlines.